Preclinical studies suggest that statins contribute to the prevention of pancreatic cancer; however, the results of epidemiologic studies are inconsistent. Furthermore, sufficient data are unavailable for the general population of Asia. Here, we conducted an observational study using a comprehensive patient-linked, longitudinal health insurance database comprising the records of 2,230,848 individuals residing in Shizuoka Prefecture, Japan, from April 2012 to September 2018. We included individuals older than 40 years with data for medical examinations and statin exposure (≥365 statin prescription days). To balance baseline characteristics between the statin exposure and statin nonexposure groups, we used inverse probability of treatment propensity score weighting method. We estimated hazard ratios for associations with pancreatic cancer using the Cox proportional hazards regression model. Among 2,230,848 individuals, we included 100,537 in the statin exposure group (24%) and 326,033 in the statin nonexposure group (76%). Among the statin exposure group (352,485 person-years) and the statin nonexposure group (1,098,463 person-years), 394 (1.12 per 1,000 person-years) and 1176 (1.07 per 1,000 person-years) developed pancreatic cancer, respectively ( P = 0.464). After adjustments using inverse probability of treatment weighting, the statin exposure group was associated with a decreased incidence of pancreatic cancer (hazard ratio, 0.84; 95% confidence intervals, 0.72–0.99; P = 0.036). In conclusion, the current Japanese regional population-based cohort study shows that statin exposure was associated with a lower incidence of pancreatic cancer. Prevention Relevance: This study may support the possible role of statins in preventing pancreatic cancer in the general population in Japan.

中文翻译：

---

他汀类药物暴露和胰腺癌发病率：一项基于日本区域人群的队列研究，静冈研究

临床前研究表明，他汀类药物有助于预防胰腺癌；然而，流行病学研究的结果并不一致。此外，对于亚洲的一般人群，没有足够的数据。在这里，我们使用一个全面的与患者相关的纵向健康保险数据库进行了一项观察性研究，该数据库包含 2012 年 4 月至 2018 年 9 月居住在日本静冈县的 2,230,848 名个人的记录。我们将 40 岁以上的个人纳入体检数据和他汀类药物暴露（≥365 他汀类药物处方日）。为了平衡他汀类药物暴露组和他汀类非暴露组之间的基线特征，我们使用了治疗倾向评分加权方法的逆概率。我们使用 Cox 比例风险回归模型估计了与胰腺癌相关的风险比。在 2,230,848 人中，他汀类药物暴露组中的 100,537 人（24%）和他汀类非暴露组中的 326,033 人（76%）。在他汀类药物暴露组（352,485 人年）和他汀类非暴露组（1,098,463 人年）中，分别有 394 人（1.12/1000 人年）和 1176 人（1.07/1000 人年）患胰腺癌（P = 0.464）。在使用治疗加权逆概率进行调整后，他汀类药物暴露组与胰腺癌发病率降低相关（风险比，0.84；95% 置信区间，0.72-0.99；P = 0.036）。综上所述，目前日本地区基于人群的队列研究表明，他汀类药物暴露与胰腺癌发病率降低有关。预防相关性：这项研究可能支持他汀类药物在日本普通人群中预防胰腺癌的可能作用。